MPM Capital

MPM BioImpact is a leading biotechnology investment firm that creates, builds, and invests in innovative private and public companies across all stages of drug development. The firm focuses on transforming scientific breakthroughs into life-saving medicines, particularly in areas like oncology, autoimmune diseases, neuroscience, and RNA therapeutics, with a strong emphasis on impact investing to improve patient outcomes. Managing over $3 billion in assets under management across early-stage venture funds, private/public impact funds, and public equities funds, MPM BioImpact combines decades of venture capital expertise with dedicated impact strategies, adhering to global standards for impact management.

MPM BioImpact evolved from MPM Capital, founded in 1996, which brought over 30 years of biotech investing experience, including backing 60 FDA-approved drugs and over 120 M&A and IPO events. The firm merged MPM Capital's venture capital track record with BioImpact's 10+ years in public investing and impact focus, leveraging Entrepreneur Partners for deep domain expertise in R&D, clinical strategy, and regulatory navigation. Headquartered in Boston, it operates as a company builder, often founding portfolio companies based on groundbreaking academic research.

Notable investments include company creations like Orna Therapeutics, pioneering circular RNA (oRNA) medicines for autoimmune and oncology indications in collaboration with Vertex Pharmaceuticals; Aktis Oncology, developing alpha radiopharmaceuticals for solid tumors with a recent upsized IPO; Reunion Neuroscience, advancing psychedelic-inspired compounds for postpartum depression and anxiety with promising Phase 2 data; and early backing of argenx, now a global leader in immunology with the approved FcRn blocker VYVGART. These highlight the firm's role in driving breakthroughs from lab to market.

The team features seasoned experts such as Managing Partner Christiana Bardon, M.D., M.B.A., who leads public market investing and holds fellowships at Harvard; Entrepreneur Partner Pankaj Bhargava, M.D., former oncology head at Gilead; and Nobel laureate Carolyn Bertozzi, Ph.D., chairing the Medical and Scientific Advisory Board with innovations in bioorthogonal chemistry. Leaders like Chairman Ansbert Gadicke, M.D., bring extensive experience in biotech company building and execution.